AXSM250117P100000
- 19.00
- +3.00+18.75%
Axsome Therapeutics Newsroom
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $180
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $140
RBC Lifts Price Target on Axsome Therapeutics to $140 From $138, Keeps Outperform Rating
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics Price Target Maintained With a $133.00/Share by Needham
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Alzheimer's Drug Study Yields Mixed Results. Wall Street Still Likes Axsome. -- Barrons.com
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Mizuho Trims Price Target on Axsome Therapeutics to $122 From $124, Keeps Outperform Rating
Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer's Agitation